Physician profile
Samreen Munir
NPI 1871978114
$531.16
in general payments reported to CMS, 2019-2025
10 companies · $52.26 in 2025
The $52.26 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.68 · 2020: $58.50 · 2021: $17.94 · 2022: $21.23 · 2023: $34.51 · 2024: $335 · 2025: $52.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $421.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $163.96 | 2024-2025 | Spravato, Invega Sustenna |
| Shockwave Medical, INC | $125.00 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Otsuka America Pharmaceutical, INC. | $62.16 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $55.44 | 2020-2025 | Uzedy |
| Abbvie INC. | $42.82 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $20.13 | 2024 | Ingrezza |
| Bioxcel Therapeutics, INC. | $18.31 | 2023 | Igalmi |
| E.R. Squibb & Sons, L.L.C. | $17.30 | 2025 | Cobenfy |
| Lundbeck LLC | $14.36 | 2020 | |
| Ironshore Pharmaceuticals INC. | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samreen Munir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.